Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704869 · ClinicalTrials.gov registry record · Phase 3
Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
A Phase 3 study of Trauma Injury, sponsored by Bryan Cotton.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,604
- Enrollment target
- 20
- Study locations
NCT04704869 is a Phase 3 study of Trauma Injury that has completed, run by Bryan Cotton. The registered enrollment target is 1,604 participants, above the 394-participant average among 15 other Trauma Injury trials with a reported enrollment target (307% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT04704869, a Phase 3 study of Trauma Injury, has completed, sponsored by Bryan Cotton.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,604 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).
Conditions Studied
Interventions
- BIOLOGICAL Cryoprecipitate
- BIOLOGICAL Red Blood Cells
- BIOLOGICAL Plasma
- BIOLOGICAL Platelets
- BIOLOGICAL Whole Blood
Study Locations (20)
Other
- Queen Elizabeth Hospital - Birmingham
- Royal Sussex County Hospital - Brighton
- Southmead Hospital - Bristol
- Addenbrooke's Hospital - Cambridge
- University Hospital of Wales - Cardiff
- University Hospital of Coventry and Warwickshire - Coventry
- Hull Royal Infirmary - Hull
- Leeds General Infirmary - Leeds
- University Hospital Aintree - Liverpool
- Royal London Hospital - London
- King's College Hospital - London
- St. George's Hospital - London
- St. Mary's Hospital - London
- Manchester Royal Infirmary - Manchester
- Salford Royal Hospital - Manchester
- James Cook University Hospital - Middlesbrough
- Royal Victoria Infirmary - Newcastle upon Tyne
- Queens Medical Centre - Nottingham
- John Radcliffe Hospital - Oxford
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,604 participants |
| Start Date | 2017-01 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04704869
The ClinicalTrials.gov registry entry for NCT04704869 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,604 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 394-participant average among 15 other Trauma Injury trials with a reported enrollment target (307% higher). The listed sponsor is Bryan Cotton, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Trauma Injury appearing as the primary indexed condition, and to 5 interventions - of which Cryoprecipitate is the first listed.
NCT04704869 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.
Frequently Asked Questions
What is clinical trial NCT04704869 about?
NCT04704869 is a clinical study titled "Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation". The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).
What is the current status of trial NCT04704869?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,604 participants. The study started on 2017-01. Estimated completion is 2022-11-01.
What conditions does trial NCT04704869 study?
This clinical trial studies the following conditions: Trauma Injury.
What interventions are being tested in trial NCT04704869?
The interventions under investigation include: Cryoprecipitate (BIOLOGICAL), Red Blood Cells (BIOLOGICAL), Plasma (BIOLOGICAL), Platelets (BIOLOGICAL), Whole Blood (BIOLOGICAL).
Who is sponsoring clinical trial NCT04704869?
This trial is sponsored by Bryan Cotton, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04704869 being conducted?
This trial has 20 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Trauma Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children
RECRUITING · Phase 3
-
Pathological Myeloid Activation After Sepsis and Trauma
RECRUITING
-
Therapy Dog Visits for Patients Hospitalized With Traumatic Injuries
RECRUITING · NA
-
Antibiotic Use in Facial Fracture Post Injury
RECRUITING
-
Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury
RECRUITING · NA
-
The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.